Psychopharmacology

The atypical antipsychotic was approved for the acute treatment of schizophrenia in 2009.

From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of March.

“The heart of the matter.” Researchers investigated the risk of cardiovascular disease associated with long-term ADHD medication use.

The treatment significantly reduced the frequency of cataplexy attacks in patients with narcolepsy compared with placebo.

From the relationship between glucose fluctuations and cognition in patients with type 1 diabetes to augmentation strategies for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

The trial aims to investigate the positive, negative, and cognitive domains of schizophrenia.

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

From an update on Prism for PTSD to the efficacy of home-use transcranial direct current stimulation for MDD, here are highlights from the week in Psychiatric Times.

This trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VLS-01 compared with intravenous DMT for treatment-resistant depression.

From personality disorders and common comorbidities to the effects of abortion bans on mental health, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the February 2024 issue of Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of February.

The CRL cited several areas for clinical improvement necessary for future approval of the treatment.

From connections between bipolar disorder and cardiometabolic issues to management of agitation in emergency departments, here are highlights from the week in Psychiatric Times.

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

What is new in research on schizophrenia?

Clinical trial compares outcomes with behavioral activation psychotherapy or antidepressant medication for depression in patients with heart failure.

Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.

What is new in research on bipolar disorder?

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

What is new in research on depression?

Here are some updates from the world of psychiatry throughout the month of January.

To divide or not to divide? Researchers compared clinical features, side effects, and blood levels between once daily versus divided clozapine dosing regimens.

The experts weighed in on a wide variety of psychiatric issues for the January 2024 issue of Psychiatric Times.

The candidate also aims to address neurodevelopmental and neurodegenerative disorders such as Parkinson disease and Rett syndrome.

From clinician wellness to THC use in adolescents, here are highlights from the week in Psychiatric Times.

The results were shared in a poster presentation at the 2024 APSARD Annual Meeting.